Mesoblast Ltd. (MESO)
17.87
+0.68
(+3.96%)
USD |
NASDAQ |
Dec 05, 16:00
17.88
+0.01
(+0.06%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.286B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 62.45% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 125.41 |
| Price to Book Value | 4.556 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 95.66% |
Profile
| Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia. |
| URL | http://www.mesoblast.com |
| Investor Relations URL | https://investorsmedia.mesoblast.com/ |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Aug. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia. |
| URL | http://www.mesoblast.com |
| Investor Relations URL | https://investorsmedia.mesoblast.com/ |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Aug. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |